From rare disease to mass market: plozasiran gets FDA green light for severe hypertriglyceridemia review
Arrowhead’s plozasiran receives FDA Breakthrough Therapy status for severe hypertriglyceridemia. Learn what this means for trials, patients, and the RNAi market. Read More
How Arrowhead Pharmaceuticals’ first FDA-approved drug Redemplo could reshape treatment for familial chylomicronemia syndrome
Discover how Arrowhead Pharmaceuticals’ FDA approval for Redemplo could transform care for familial chylomicronemia syndrome. Read More
Biotech rivals clash as Arrowhead sues Ionis over RNA-based triglyceride therapy
Arrowhead sues Ionis over APOC3 patent dispute as plozasiran nears FDA approval. Discover what’s at stake in this RNA-based biotech rivalry. Read More
Arrowhead Pharmaceuticals advances plozasiran for familial chylomicronemia syndrome with FDA NDA acceptance
Arrowhead Pharmaceuticals, Inc. has taken a major step toward addressing a critical gap in rare disease treatment. The U.S. Food and Drug Administration (FDA) has ... Read More